Bupropion HCl MR tablets 300mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence
Conditions
Bioequivalence
Trial Timeline
Jan 18, 2020 → Feb 5, 2020
NCT ID
NCT05160090About Bupropion HCl MR tablets 300mg
Bupropion HCl MR tablets 300mg is a phase 1 stage product being developed by Alembic Pharmaceuticals for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT05160090. Target conditions include Bioequivalence.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05160090 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence